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Objectives: Evidence for an association between duration of untreated illness (DUI) with clinical and
functional outcome or brain volume (change) in schizophrenia patients is inconclusive. We aimed to
investigate the relationship between DUI, outcome and brain volume at illness onset or brain volume change
during the ﬁrst ﬁve years of the illness in ﬁrst-episode patients.
Methods:Magnetic resonance images were acquired at baseline (T0) and after 5-year (T5) of 57 schizophrenia
patients. Correlations were calculated in patients between brain volume (change), DUI and outcome variables.
Results: We found no signiﬁcant correlation between DUI and brain volume (change) in schizophrenia
patients. A longer DUI was signiﬁcantly correlated with higher PANSS scores at T0 and T5, and with higher
scores on the Camberwell Assessment of Need scale at T5. Baseline volume of the cerebrum and lateral
ventricles, and cerebellum volume (change) were associated with PANSS scores at T0 and T5.
Conclusion: Although clinical outcome is associated with both brain volume (change) and DUI, we found no
evidence for a relationship between DUI and brain volume (change). DUI and baseline brain volume or 5-year
brain volume (change) seem to explain different parts of the variation in clinical outcome.
© 2011 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
Schizophrenia is, in the majority of cases, characterized by an
insidious onset, often preceded by a decline in functioning. Duration
of untreated psychosis (DUP), prodrome (DPD) and untreated illness
(DUI) have all been used to characterize the period before the start of
treatment or the onset of psychosis. DUP is the time between onset of
psychosis and the start of treatment, which is generally deﬁned as
hospitalization (Madsen et al., 1999; Perkins et al., 2005; Bangalore et
al., 2009) or (adequate) antipsychotic treatment (Perkins et al., 2005;
Crespo-Facorro et al., 2007a; Selten et al., 2007; Emsley et al., 2008;
Crumlish et al., 2009). Onset of psychosis is usually determined
retrospectively and is deﬁned as the onset of ﬁrst psychotic symptoms
(Perkins et al., 2005; Lappin et al., 2006; Crespo-Facorro et al., 2007a;
Selten et al., 2007; Emsley et al., 2008; Bangalore et al., 2009).
The start of DPD is usually deﬁned as a persistent deviation from
the individual's normal premorbid functioning, behavior or personality
and/or the emergence of prodromal psychiatric symptoms that do notPsychiatry and Addiction,WA-
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vier OA license. fulﬁll the criteria for psychosis (Loebel et al., 1992; Crespo-Facorro et al.,
2007a; Bangalore et al., 2009; Crumlish et al., 2009; Ebdrup et al., 2010;
O'Callaghan et al., 2010). It ends at the emergence of psychotic
symptoms. Finally, DUI is deﬁned as the sum of DUP and DPD.
Clinical and social outcome variables have been associated with DUI
(Loebel et al., 1992; Crumlish et al., 2009; Owens et al., 2010) and DPD
(Malla et al., 2002; Harrigan et al., 2003; Fusar-Poli et al., 2009) in that
longer DUI or DPD correlated with poorer outcome. However, others
could not replicate such a relationship (Barnes et al., 2000; Craig et al.,
2000; Ho et al., 2000; Hoff et al., 2000; Norman et al., 2001; Malla et al.,
2002; Harrigan et al., 2003; Selten et al., 2007; Gonzalez-Blanch et al.,
2008). A small to moderate effect of DUP on outcome in schizophrenia,
including symptom remission and functional rehabilitation has been
established in two reviews (Marshall et al., 2005; Perkins et al., 2005).
Interestingly, poorer outcome has also been associated with
smaller brain volumes (Buchsbaum et al., 2003; Molina et al., 2010),
larger ventricles (DeLisi et al., 2004) and excessive brain volume loss
over time (Cahn et al., 2002; Cahn et al., 2006; Van Haren et al., 2008),
for review see (Hulshoff Pol and Kahn, 2008; Kempton et al., 2010).
Therefore, we hypothesize that DUP, DUI or DPD through their effect
on outcome, are associated with (change in) brain volume abnormal-
ities in schizophrenia patients or vice versa. Consequently, a longer
delay of treatment would be related to larger decline of brain volume.
Indeed, cross-sectional studies provide evidence for an association
between brain abnormalities and a longer DUP, DUI or DPD
(Angelopoulos et al., 2002; Bangalore et al., 2009; Crespo-Facorro
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Madsen et al., 1999; Penttila et al., 2010; Takahashi et al., 2007;
Théberge et al., 2004). So far, only one longitudinal study investigated
the relationship between DUP, outcome and global brain volume
change over time using computed tomography (CT), and found no
evidence for such a relationship (Madsen et al., 1999). The advantage
of longitudinal studies is that repeated observation in the same
individual are obtained and these may have more power than
observations from cross-sectional studies do.
The present study aimed to investigate the relationship between
DUI, global brain volume (change), and outcome in ﬁrst-episode
schizophrenia patients.
2. Materials and methods
2.1. Subjects and design
Patients, aged 17–40 years, with a maximum antipsychotics expo-
sure of 6 months, were recruited from The First Episode Schizophrenia
Research Program at the University Medical Center, Utrecht, The
Netherlands. After complete description of the study written informed
consent was obtained from all participants. The Medical Ethics Review
Board of the UniversityMedical Centre Utrecht approved the study. This
study was performed in accordance with the Declaration of Helsinki.
Patientswhohad anMRI scanat inclusion (T0) andwhowerediagnosed
according to DSM-IV criteria with schizophrenia at follow-up (T5)were
included. Diagnosis was assessed with the Comprehensive Assessment
of Symptoms and History Schizophrenia (Andreasen et al., 1992). The
PositiveandNegativeSyndromeScale (PANSS)wasperformedatT0and
T5 (Kay et al., 1987, 1988). At T5 both the Global Assessment of
Functioning (GAF) and the Camberwell AssessmentofNeed (CAN)were
performed (Endicott et al., 1976; Goldman et al., 1992; Phelan et al.,
1995). Course of illness data to determine DUI was collected
retrospectively using patient reports prompted by key data and data
from a shortened version of the Interview for the Retrospective
Assessment of the Onset of schizophrenia (IRAOS) at T5 (Hafner et al.,
1992). Furthermore, a careful examination of the medical records was
carried out and the treating psychiatrist and/or key worker were
interviewed.
The duration of untreated illness (DUI) was deﬁned as the period
fromonset of prodrome to the start of antipsychotic treatment. Criterion
B from the DSM-III was used to deﬁne onset of prodrome (when one or
more major areas of functioning such as work, interpersonal relations,
or self care are markedly below the level achieved prior to the onset).
Consensuswas reachedbetween two independent researchers (WCand
TCM) about the date the prodrome started.
To calculate the lifetime cumulative dosage of antipsychotic
medication up to T0 and T5, a careful examination of the medical
records was carried out. A table from the Dutch National Health Service
was used to derive the haloperidol equivalents for typical antipsychotics
(No authors listed, 2007) (conversion rates: broomperidol 1:1, droper-
idol 1:1, haloperidol 1:1, penﬂuridol 1:1, perfenazine 5:1, pimozide
0.85:1, pipamperon 50:1, zuclopentixol 5:1). For atypical antipsychotic
medication, the respective pharmaceutical companies suggested con-
version rates into haloperidol equivalents (H-EQ) (clozapine, 40:1;
olanzapine, 2.5:1; quetiapine, 50:1; risperidone, 1:1; sulpiride, 170:1).
In addition, 56 controls were included, group-matched for age,
gender and handedness, in order to assess whether this patient
sample shows the expected brain abnormalities (i.e., smaller cerebral
(gray matter) volume at baseline, and excessive gray matter volume
loss over time in patients relative to controls).
2.2. MRI data acquisition
Magnetic resonance images (MRIs) were acquired using a 1.5 Tesla
Philips NT scanner. Volume measures of the intracranium, total brain(TB), cerebral gray (GM) and white matter (WM), cerebellum (CB),
third (V3) and lateral ventricles (LV) were determined. Acquisition
parameters and processing have been described previously (Schnack
et al., 2001a,b; Van Haren et al., 2003) All segmentations were
checked and corrected manually if necessary. The interrater re-
liabilities of the volume measurements, determined by the ICC were
0.95 and higher.
2.3. Data-analysis
Data were checked with the Pearson's Chi-Square test for nominal
variables, ANOVA for normally distributed, and Mann–Whitney U test
for abnormally distributed continuous variables (Table 1). Brain volume
(change)was corrected for IC, age and gender usingmultiple regression
analyses. Unstandardized residuals were saved and used in the main
analysis. The difference in volume (change) between patients and
controls was tested using ANOVA for normally distributed, and Mann–
Whitney U test for abnormally distributed volume variables. Pearson's
correlation coefﬁcients, or Spearman Rank correlation coefﬁcients in
not-normally distributed variables, were calculated to investigate
the association between 1) DUI and corrected brain volume (change)
2) clinical outcomemeasures (PANSS total and subscores at T0 and T5,
GAF and CAN professional total score at T5) and DUI, and 3) clinical
outcomemeasures and corrected brain volume (change). The signiﬁcant
associations were corrected for intake of alcohol or drugs in the three
months prior to the study with partial correlations.
At baseline, 36 patients were medication-naïve and correlation
analyses on baseline measures of outcome, brain volume and DUI
were performed in this subgroup to exclude the inﬂuence ofmedication
effects.
SPSS18 was used for all analyses. Only ﬁndings with pb0.01 are
presented.
3. Results
3.1. Brain volume (change) in patients and controls
At baseline V3 was larger in patients compared to controls.
Patients, compared to controls, showed amore pronounced loss of GM
over a ﬁve year interval (Table 1).
3.2. DUI and brain volume (change)
No signiﬁcant correlations were found between brain volume
(change) and DUI (Table 2).
3.3. DUI and clinical outcome
Signiﬁcant associations were found between DUI and clinical and
functional outcome, indicating larger DUI to be related to poorer
outcome (Table 2, Fig. 1). Longer DUI was signiﬁcantly correlated
with higher PANSS total scores at T5 (ρ=.42, p=.003), PANSS positive
score at T0 and T5 (T0:ρ=.37, p=.008, T5: ρ=.53, p=.00009) and the
PANSS general score at T5 (ρ=.37, p=.01). Furthermore, there was a
positive correlation between DUI and the CAN total score at T5 (ρ=.41,
p=.004).
3.4. Brain volume (change) and clinical outcome
Signiﬁcant correlations were found between brain volume (change)
and level of symptoms at baseline and follow-up measurement
(Table 2). There was a negative correlation between baseline TB and
the negative PANSS score at T0 and T5 (T0: r=− .44, p=.002; T5: ρ=
− .40, p=.005). CB change was negatively correlated with the PANSS
general score at T0 (r=− .43, p=.01). These correlations suggest that
the presence of more symptoms is related to more CSF and less brain
Table 1
Baseline characteristics for all patients, and those patients with both a baseline and a 5-year follow-up scan, as well as for all controls and those controls with both a baseline and a 5-
year follow-up scan. Mean baseline brain volumes and mean 5-year change in brain volume in patients and controls.
Variables, mean (sd) Patients Controls
T0, N=57 T0+T5, N=42 T0, N=56 T0+T5, N=37
Age, (yr) 24.7 (5.8) 24.0 (5.3) 24.8 (5.9) 25.0 (6.7)
Gender (male/female) (n) 51/6 37/5 49/7 31/6
Total education of the subject (yr) 12.0 (2.6) 12.1 (2.6) 14.3 (2.6) a 14.6 (2.6) a
Highest level of parental education (yr) 12.9 (3.6) 13.7 (3.4) a 12.3 (5.0) b 13.7 (2.8)
Handedness (percentage right/left/ambidexter/missing) (n) 49/2/5/1 35/2/4/1 40/5/2/9 28/4/0/5
Naïve/T/AT/both (n) 36/12/5/4 27/8/4/3 – –
Abuse of drugs within 3 months before the ﬁrst MRI (no/yes) 31/25 22/19 – –
Abuse of drugs ever before the ﬁrst MRI (no/yes) 23/34 16/26 – –
PANSS total score at T0 73.4 (16.8) 74.3 (17.6) – –
PANSS positive symptom score at T0 18.0 (5.8) c 17.7 (5.5) – –
PANSS negative symptom score at T0 19.6 (5.3) 19.1 (5.4) – –
PANSS general symptom score at T0 37.2 (9.4) 38.0 (9.7) – –
Duration of untreated illness, weeks 313.4 (316.8) 270.6 (238.8) – –
Brain volume, ml, mean (sd) Baseline
N=57
Change, (T5–T0)
N=42
Baseline
N=56
Change, (T5–T0)
N=37
Total brain 1324.63 (110.13) −2.72 (6.29) 1350.93 (122.62) −1.16 (3.74)
Cerebral gray matter 810.28 (67.00) −6.61 (6.44) e 698.36 (68.52) −2.60 (4.6)
Cerebral white matter 514.35 (62.43) 3.29 (4.84) 489.10 (66.11) .95 (4.4)
Cerebellum 147.21 (12.84) .45 (.75) 49.03 (12.69) .16 (.53)
Third ventricle .85 (.40) d .02 (.04) .72 (.31) .00 (.02)
Lateral ventricles 14.73 (8.28) .33 (.65) 14.88 (8.78) .14 (.24)
T0=baseline, T5=follow-up at 5 years, T0+T5=baseline and follow-up measurement present, T=typical antipsychotics, AT=atypical antipsychotics, PANSS=positive and
negative syndrome scale, ml=milliliter.
a Mean total education was higher in controls (NCS) compared to patients (PTS), both in groups with only a scan at T0 (pb .01) and groups with T0+T5 (pb .01).
b Parental education was signiﬁcantly higher in PTS with T0+T5 MRI scan compared to PTS with only a T0 scan (pb .01).
c The PANSS positive score was signiﬁcantly higher in medication naïve PTS (NP's) as compared to medicated PTS (MP's) (p=.02). Mean total education in years was signiﬁcantly
higher in NCS compared to NP's (pb0.01) (data not shown). The PANSS positive score was signiﬁcantly higher in NP's compared to MP's (p=.02) (data not shown).
d The difference between baseline third ventricle volume (corrected for age, gender and baseline intracranial volume) in PTS and NCS was signiﬁcant (p=.001).
e The difference in cerebral graymatter (GM) change (corrected for age, gender and baseline intracranial volume) was signiﬁcant between NCS and PTS (p=.01). In NP's we found
a larger baseline cerebral GM (corrected for age, gender and baseline intracranial volume) than in MP's (data not shown).
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to baseline LV (r=− .34,p=.009) andpositively to CB (r=.36, p=.01).
After correction for alcohol or drugs intake the study the ﬁndings
remained the same.3.5. Medication naïve patients
Medication naïve patients (n=36) showed no signiﬁcant
correlations between baseline brain volume and DUI or outcome.Table 2
Pearsons correlation or Spearman's (ρ) coefﬁcients between brain volume (change), durati
Baseline
brain volume
n=57 n=42 n=49 n=49 n=42
DUI
(ρ)
T0 PANSS
total score
T0 PANSS
positive score
T0 PANSS
negative score
T0 PANSS
general score
Total brain .08 −.31 − .06 − .44a − .22
Cerebral gray matter − .05 − .20 − .07 − .26 − .15
Cerebral white matter − .05 − .18 − .01 − .23 − .13
Cerebellum .25 .08 .03 − .17 .08
Third ventricle − .09 .16 − .01 .33 .13
Lateral ventricles − .09 − .20 − .06 .06 − .16
Brain volume change n=42 n=35 n=38 n=38 n=35
Total brain − .30 − .03 − .10 .17 − .10
Cerebral gray matter − .08 .00 .08 .10 − .04
Cerebral white matter − .16 − .01 − .22 .09 − .04
Cerebellum − .20 − .37 − .25 − .14 − .43a
Third ventricle .10 − .14 − .01 − .22 − .11
Lateral ventricles .17 − .16 .14 (ρ) − .13 (ρ) − .00
DUI − n=42 n=49 n=49 n=42
DUI (ρ) − .33 .37a .10 .35
a p≤0.01 (signiﬁcant), ml=milliliter, PANSS=Positive And Negative Syndrome Scale
Correlations are Pearsons correlations coefﬁcients unless indicated otherwise.In medication-naïve patients DUI was signiﬁcantly longer in patients
with a higher baseline PANSS general score (ρ=.49, p=.01).
4. Discussion
We investigated the association between duration of untreated
illness (DUI), brain volume (change), and clinical outcome in ﬁrst-
episode schizophrenia patients. Our main ﬁnding was the lack of
association between DUI and brain volume at illness onset or brain
volume change during the ﬁrst ﬁve years of illness. We did identifyon of untreated illness (DUI) and functional and clinical outcome.
n=48 n=48 n=48 n=48 n=41 n=48
T5 PANSS
total score
T5 PANSS
positive score
T5 PANSS
negative score (ρ)
T5 PANSS
general score (ρ)
T5 GAF
score
T5 CAN
score
− .13 .03 − .40a − .23 .19 .03
− .11 − .10 − .20 − .13 .10 .08
− .08 .01 − .18 − .12 .18 − .07
.09 .36a − .08 .13 − .11 .03
− .01 − .19 .32 .11 − .09 − .06
− .17 − .37a − .13 − .30 .13 .03
n=41 n=41 n=41 n=41 n=36 n=41
− .13 − .10 − .17 − .11 .34 − .29
− .04 − .02 − .20 − .15 .31 − .16
− .07 − .12 .08 12 .04 − .13
− .16 − .22 − .32 − .25 .26 − .20
− .08 − .00 .10 .01 − .29 .22
.04 .02 .10 .01 − .23 (ρ) .32
n=48 n=48 n=48 n=48 n=41 n=48
.42a .53a .18 .37a − .29 .41a
, GAF=Global Assessment of Functioning, CAN=Camberwell Assessment of Need.
Fig. 1. Association between positive symptoms and level of need at T5 and duration of
illness in schizophrenia patients.
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up with both DUI and brain volume (change). It seems that DUI and
brain volume explain different parts of the variance in clinical outcome
in ﬁrst-episode schizophrenia patients. Based on our ﬁndings onemight
argue that attempts to shorten DUI will not result in diminished
progressive brain volume decreases in patients with schizophrenia,
though it might improve clinical outcome.
4.1. DUI and brain volume (change)
Our ﬁnding is in line with the only longitudinal (CT) study that
found no relationship between DUP and 5-year change in frontal brain
atrophy in 24 ﬁrst-episode schizophrenia patients (Madsen et al.,
1999). Two cross-sectional MRI studies, using either a volumetric or a
voxel-based morphometry (VBM) approach showed associations
between longer DUI and decreased volume or gray matter density
in small cortical areas in ﬁrst-episode schizophrenia patients, i.e.,
superior temporal gyrus, fusiform gyrus, lingual and parahippocampal
gyrus (Keshavan et al., 1998; Bangalore et al., 2009). However, other
cross-sectional studies found no associations between DUI and brain
volume of the thalamus, caudate nucleus, hippocampus, (lateral)
ventricles, temporal lobe and cerebral hemispheric volumes (Hoff
et al., 2000; Crespo-Facorro et al., 2007a,b; Ebdrup et al., 2010). Thus,
if there is a relation between DUI and brain volume (change), it might
be restricted to focal areas of the brain.
Findingno association betweenDUI andbrain volume loss in theﬁrst
ﬁve years of the illnessmight be confoundedby the start of antipsychotic
medication. Patients received different kinds of antipsychotics and it isknown that types of antipsychotic medication might have either a
decrease or increase in brain volumes over time (Ho et al., 2011; Van
Harenet al., in press). Evidence so far suggests that antipsychotics cannot
explain all of the brain volume abnormalities in patients (Navari and
Dazzan, 2009; Moncrieff and Leo, 2010).
4.2. DUI and clinical outcome
The association between DUP, DUI and DPD and the course of
schizophrenia is well established (Marshall et al., 2005; Perkins et al.,
2005), amongst others in studies with a follow-up of 5 year or more
(Bottlender et al., 2002; DeHaan et al., 2003; Gunduz-Bruce et al., 2005;
Harris et al., 2005; Crumlish et al., 2009; White et al., 2009). Consistent
with this, we found DUI to be longer in the presence of poor functional
and symptomatic outcome both at baseline and at follow-up measure-
ment. Most convincing was the association between DUI and positive
symptoms.
Clarke showed that longer DUI predicted more severe PANSS
positive symptoms at 4-year follow-up in ﬁrst-episode schizophrenia
patients (Clarke et al., 2006). However, other studies failed to ﬁnd a
correlation between positive symptom scores and DUI in ﬁrst-episode
schizophrenia (Barnes et al., 2000; Ho et al., 2000; Barnes et al., 2008;
Gonzalez-Blanch et al., 2008).
At follow-up, the GAF score and DUI were not correlated. This is
interesting as several studies suggested such a correlation, with
intervals ranging from one to four years (Keshavan et al., 2003; Cahn
et al., 2006; Clarke et al., 2006; Fusar-Poli et al., 2009). These studies
investigated patients that were on medication, which obviously affects
the symptom levels. Importantly, we included 36 medication naïve
patients in whom correlations between symptomatic and functional
outcome at baseline and DUI were in the same direction and of similar
(or larger) magnitude compared to the total sample. However, due
to the smaller size of this sample not all reached signiﬁcance. In
summary, we replicated the associations between DUI and psychiatric
symptomatology at baseline, and afterﬁve years inmedicated aswell as
medication-naïve patients.
4.3. Brain volume (change) and outcome
Showing more positive symptoms at follow-up was related to a
smaller lateral ventricle and larger cerebellum at baseline. These
correlations seem counterintuitive. One would expect smaller volumes
or more pronounced loss to be associated with more severe symptoms
(Hulshoff Pol and Kahn, 2008; Kempton et al., 2010). Effects in this
direction have indeed been shown previously in the cerebellum
(Wassink et al., 1999; Premkumar et al., 2009). However, we are not
the ﬁrst to ﬁnd larger cerebellar volumes to be related to poorer
outcome (Levitt et al., 1999; Yoshihara et al., 2008). It is important to
note though that there is a long delay between themeasurement of the
volumes (T0) and the symptom level (T5). As the PANSS scores
symptom levels based on the previous week these associations might
not be reliable.
We also showed that lower total brain volume was associated with
more negative symptoms both at illness onset as well as at follow-up
measurement which is in line with earlier studies from our group
including overlapping samples (Cahn et al., 2002, 2006; VanHaren et al.,
2008). These ﬁndings also corroborate with ﬁndings in antipsychotic-
naïve ﬁrst-episode patients that showed reduced temporal and frontal
baseline volumes to be associated with less improvement of negative
symptoms over 30 months (Gur et al., 1998), while (progressive) gray
matter deﬁcits identiﬁed in a VBM study in chronic schizophrenia
patients were found to be associated with negative symptoms
(Mathalon et al., 2001). One other ﬁrst-episode study found the volume
of focal areas (with VBM) to be inversely related to theGAF score (Mané
et al., 2009). However, other research by our group did not identify
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Haren et al., 2003).
In medication-naïve patients we found equally large correlations,
although not signiﬁcant because of the smaller number of patients,
between PANSS total and negative score and baseline TB and third
ventricle volume.
4.4. Strengths and limitations
We included patients aged 17 to 40 of whom 12 were aged 30 or
more at inclusion. Developing schizophrenia after 30 years of age is
uncommon, it can be that patients are ill for a long time before being
introduced to mental health care. This seems to have been the case
since therewas a long DUI in these older patients compared to the rest
of the patient group, namely 11.6 years (standard deviation (sd) 5.3)
versus 3.9 (sd 3.8) years.
Unfortunately, the IRAOS, which aims to measure the onset of
schizophrenia was only completed at follow-up measurement. This
increases the possibility of inaccurate data due to memory bias. It is
difﬁcult to determine DUI, DUP or DPD prospectively, since prediction
of psychosis and prodrome is not yet feasible in clinical practice
(Cannon et al., 2008). Furthermore, problems related to memory exist
in studies investigating DUI, DUP and DPD (Guay, 1982; Coughlin,
1990; Aleman et al., 1999; Croyle et al., 2006). To ensure internal
validity we obtained consensus between two investigators about the
time of onset of prodrome.
An important confounder is level of premorbid functioning. DUI
was deﬁned as the period from onset of prodrome to the start of
antipsychotic treatment. Onset of prodrome was deﬁned as a decline
in functioning in one or more major areas (e.g., work, interpersonal
relations, self care), markedly below the level achieved prior to the
onset. What we looked for was a relatively sudden and clear decline in
the level of functioning. Whether individuals were high or low
functioning at the time of this change was not relevant. In that sense,
level of premorbid functioning is unrelated to DUI. However, there
might still be an association. As we did not obtain information on
premorbid functioning we cannot exclude this possibility.
ThemeanDUI determined in our study (313.4 weeks), is higher than
previously reported DUIs that vary from 119 to 227 weeks (Robinson
et al., 1999;Malla et al., 2006). This might be a consequence of the large
variation in deﬁning onset of illness, which differs from “ﬁrst behavioral
changes related to the illness” (Rabiner et al., 1986; Loebel et al., 1992;
Harrison et al., 1999; Robinson et al., 1999) or “ﬁrst personality and
behavioral changes (Barnes et al., 2000)” to “ﬁrst non-speciﬁc
(psychiatric) symptom related to psychosis” (Malla et al., 2002;
Gonzalez-Blanch et al., 2008) or a combination of these (Keshavan
et al., 2003; Clarke et al., 2006; Fusar-Poli et al., 2009; O'Callaghan et al.,
2010). The deﬁnition we used is well described and has been used
before (Selten et al., 2007). In future studies deﬁnitions of DPD, DUP and
DUI should be clear as these deﬁnitions determine the length of these
periods. Thus, what measure is used to deﬁne onset of prodrome,
psychosis or active treatment may be relevant for the subsequent
ﬁndings of the study.
In our study we followed the patients from start of treatment to
5 years after this. However, DUI was determined retrospectively
resulting in a weak test of a causal relationship between DUI and brain
structure or outcome.
4.5. Conclusion
We hypothesized that through a shared association with outcome
DUI would be associated with (change in) brain volume. However,
although associations of baseline and 5-year follow-up symptom
scores with both DUI as well as cerebral volume (change) were
identiﬁed in ﬁrst-episode patients, no associations were found
between DUI and brain volume (change). Therefore, it seems thatbrain volume at illness onset and excessive tissue loss over time
during the ﬁrst years of the illness and DUI explain a different part of
the variation in symptomatic and functional outcome.
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